Published in J Clin Invest on February 02, 2015
MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol (2016) 0.97
MicroRNA regulation of lymphocyte tolerance and autoimmunity. J Clin Invest (2015) 0.92
The dichotomous nature of T helper 17 cells. Nat Rev Immunol (2017) 0.81
Linking diet to acne metabolomics, inflammation, and comedogenesis: an update. Clin Cosmet Investig Dermatol (2015) 0.81
The role of microRNA-31 and microRNA-21 as regulatory biomarkers in the activation of T lymphocytes of Egyptian lupus patients. Rheumatol Int (2016) 0.78
MicroRNAs: The Role in Autoimmune Inflammation. Acta Naturae (2016) 0.78
Increased Th17 cells and IL-17A exist in patients with B cell acute lymphoblastic leukemia and promote proliferation and resistance to daunorubicin through activation of Akt signaling. J Transl Med (2016) 0.78
miRNAs Participate in MS Pathological Processes and Its Therapeutic Response. Mediators Inflamm (2016) 0.77
MicroRNA-21, T helper lineage and autoimmunity. Oncotarget (2015) 0.77
Regulation of IL-17 in autoimmune diseases by transcriptional factors and microRNAs. Front Genet (2015) 0.77
miRNAs as new molecular insights into inflammatory bowel disease: Crucial regulators in autoimmunity and inflammation. World J Gastroenterol (2016) 0.76
A Fleeting Glimpse Inside microRNA, Epigenetics, and Micropeptidomics. Adv Exp Med Biol (2015) 0.76
MicroRNA223 promotes pathogenic T-cell development and autoimmune inflammation in central nervous system in mice. Immunology (2016) 0.76
Adiponectin Suppresses T Helper 17 Cell Differentiation and Limits Autoimmune CNS Inflammation via the SIRT1/PPARγ/RORγt Pathway. Mol Neurobiol (2016) 0.76
Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells. Clin Epigenetics (2016) 0.76
The MicroRNA-21 in Autoimmune Diseases. Int J Mol Sci (2016) 0.76
Is It worth Considering Circulating microRNAs in Multiple Sclerosis? Front Immunol (2016) 0.75
miR-21 alters circulating Treg function in vascular disease-hope for restoring immunoregulatory responses in atherosclerosis? Ann Transl Med (2017) 0.75
Microbiota-specific Th17 Cells: Yin and Yang in Regulation of Inflammatory Bowel Disease. Inflamm Bowel Dis (2016) 0.75
MiR-384 Regulates the Th17/Treg Ratio during Experimental Autoimmune Encephalomyelitis Pathogenesis. Front Cell Neurosci (2017) 0.75
Intracranial delivery of interleukin-17A via adeno-associated virus fails to induce physical and learning disabilities and neuroinflammation in mice but improves glucose metabolism through AKT signaling pathway. Brain Behav Immun (2015) 0.75
Immunopathogenesis of systemic lupus erythematosus and rheumatoid arthritis: The role of aberrant expression of non-coding RNAs in T cells. Clin Exp Immunol (2016) 0.75
miRNA92a targets KLF2 and the phosphatase PTEN signaling to promote human T follicular helper precursors in T1D islet autoimmunity. Proc Natl Acad Sci U S A (2016) 0.75
The Microbiota and Epigenetic Regulation of T Helper 17/Regulatory T Cells: In Search of a Balanced Immune System. Front Immunol (2017) 0.75
Immunopathology alters Th17 cell glucocorticoid sensitivity. Allergy (2016) 0.75
Chromatin Remodeling Protein SMAR1 Is a Critical Regulator of T Helper Cell Differentiation and Inflammatory Diseases. Front Immunol (2017) 0.75
Expression of miRNA-155, miRNA-223, miRNA-31, miRNA-21, miRNA-125b, and miRNA-146a in the Inflammatory Pathway of Hidradenitis Suppurativa. Inflammation (2016) 0.75
1,25-Dihydroxyvitamin D3 Does Not Affect MicroRNA Expression When Suppressing Human Th17 Differentiation. Med Sci Monit (2017) 0.75
Marijuana-derived Δ-9-tetrahydrocannabinol suppresses Th1/Th17 cell-mediated delayed-type hypersensitivity through microRNA regulation. J Mol Med (Berl) (2016) 0.75
MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles. Oncogene (2017) 0.75
The functions of animal microRNAs. Nature (2004) 64.85
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell (2006) 33.94
TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity (2006) 29.29
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73
Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 25.94
Transforming growth factor-beta induces development of the T(H)17 lineage. Nature (2006) 25.91
IL-17 and Th17 Cells. Annu Rev Immunol (2009) 23.02
IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature (2007) 16.59
Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature (2007) 14.28
T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity (2007) 13.29
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 13.20
Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity (2007) 12.12
LNA-mediated microRNA silencing in non-human primates. Nature (2008) 11.45
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature (2008) 10.73
STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem (2007) 10.41
miR-21-mediated tumor growth. Oncogene (2006) 9.90
A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med (2007) 8.97
Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol (2010) 7.75
Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature (2010) 7.50
Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem (2007) 7.46
RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol (2011) 6.96
C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol (2009) 5.97
STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell (2010) 5.67
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63
The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol (2011) 5.41
Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol (2007) 5.27
Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol (2009) 5.05
miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med (2010) 4.71
Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol (2006) 4.44
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene (2008) 4.43
Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol (2009) 3.88
The AP-1 transcription factor Batf controls T(H)17 differentiation. Nature (2009) 3.75
Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. J Immunol (2009) 3.49
Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol (2001) 2.97
Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity (2013) 2.69
Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nat Immunol (2012) 2.49
Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat Immunol (2011) 2.47
Role of SMAD and non-SMAD signals in the development of Th17 and regulatory T cells. J Immunol (2010) 2.20
IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc Natl Acad Sci U S A (2008) 2.13
MicroRNA-21 limits in vivo immune response-mediated activation of the IL-12/IFN-gamma pathway, Th1 polarization, and the severity of delayed-type hypersensitivity. J Immunol (2011) 2.00
'Yin-Yang' functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol Rev (2007) 1.98
Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol (2011) 1.93
Foxp3(+) regulatory T cells promote T helper 17 cell development in vivo through regulation of interleukin-2. Immunity (2011) 1.87
Smad2 and Smad3 are redundantly essential for the TGF-beta-mediated regulation of regulatory T plasticity and Th1 development. J Immunol (2010) 1.86
Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A (2012) 1.72
IL-17-producing γδ T cells and innate lymphoid cells. Eur J Immunol (2012) 1.66
Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res (2009) 1.58
Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl Res (2012) 1.54
Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis (2011) 1.49
Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res (2011) 1.48
T(H)17 cytokines in autoimmune neuro-inflammation. Curr Opin Immunol (2011) 1.40
miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia (2013) 1.39
Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol Med (2011) 1.38
MicroRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination. Proc Natl Acad Sci U S A (2012) 1.24
Smad3 is essential for TGF-beta 1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation. J Immunol (2004) 1.24
Transforming growth factor beta and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site. Mol Cell Biol (1993) 1.19
SMAD2 is essential for TGF beta-mediated Th17 cell generation. J Biol Chem (2010) 1.18
Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neurosci Lett (2011) 1.15
P38 MAP kinase signaling is required for the conversion of CD4+CD25- T cells into iTreg. PLoS One (2008) 1.14
Smad3 binding to the foxp3 enhancer is dispensable for the development of regulatory T cells with the exception of the gut. J Exp Med (2012) 1.12
Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet. J Neuroinflammation (2011) 1.11
The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells. J Clin Invest (2012) 1.10
GM-CSF: the secret weapon in the T(H)17 arsenal. Nat Immunol (2011) 1.09
MicroRNA-21 knockout improve the survival rate in DSS induced fatal colitis through protecting against inflammation and tissue injury. PLoS One (2013) 1.02
TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2. Blood (2010) 1.01
Requirements of transcription factor Smad-dependent and -independent TGF-β signaling to control discrete T-cell functions. Proc Natl Acad Sci U S A (2012) 1.00
MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis. Exp Dermatol (2012) 0.96
The kinase PKCα selectively upregulates interleukin-17A during Th17 cell immune responses. Immunity (2013) 0.81
MicroRNAs and multiple sclerosis: from physiopathology toward therapy. Expert Opin Ther Targets (2013) 0.78
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature (2008) 9.32
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med (2004) 8.98
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet (2009) 7.16
Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell (2011) 7.03
Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med (2003) 6.73
Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature (2013) 6.50
A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol (2007) 6.20
Medical sequencing at the extremes of human body mass. Am J Hum Genet (2007) 5.61
Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature (2013) 4.74
Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature (2013) 4.57
Induction and molecular signature of pathogenic TH17 cells. Nat Immunol (2012) 4.43
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α-PU.1 pathway. Nat Med (2010) 4.24
The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol (2010) 4.06
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol (2007) 3.48
Oral tolerance. Immunol Rev (2005) 3.48
Combinatorial patterning of chromatin regulators uncovered by genome-wide location analysis in human cells. Cell (2011) 3.20
Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int (2011) 3.05
A high-throughput chromatin immunoprecipitation approach reveals principles of dynamic gene regulation in mammals. Mol Cell (2012) 3.04
Oral tolerance. Immunol Rev (2011) 3.03
Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol (2010) 3.03
Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol (2010) 3.00
Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med (2006) 2.93
Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol (2006) 2.75
Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest (2012) 2.67
Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol (2010) 2.64
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A (2008) 2.57
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol (2009) 2.56
T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proc Natl Acad Sci U S A (2010) 2.41
The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A (2009) 2.38
Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary. Nat Rev Drug Discov (2008) 2.30
An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2010) 2.21
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol (2004) 2.11
Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci U S A (2010) 2.10
Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am J Kidney Dis (2008) 2.05
High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation (2007) 2.01
IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J Immunol (2009) 2.00
Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicol Sci (2007) 1.94
Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury. Kidney Int (2009) 1.94
Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol (2011) 1.93
Tubular kidney injury molecule-1 in protein-overload nephropathy. Am J Physiol Renal Physiol (2006) 1.85
Systematic discovery of TLR signaling components delineates viral-sensing circuits. Cell (2011) 1.83
Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation (2002) 1.80
PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell Immunol (2004) 1.78
CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. J Immunol (2003) 1.75
IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol (2006) 1.72
Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging (2009) 1.70
What does the future hold for cell-based tolerogenic therapy? Nat Rev Immunol (2007) 1.64
Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol (2006) 1.63
A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. Autoimmun Rev (2006) 1.62
Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest (2008) 1.61
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest (2003) 1.59
TGF-beta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling. J Immunol (2006) 1.58
Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy. J Magn Reson Imaging (2002) 1.57
Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis. Ann Neurol (2010) 1.56
Biomarkers of nephrotoxic acute kidney injury. Toxicology (2008) 1.55
Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J Neurol Sci (2005) 1.54
Immunotherapeutic approaches to Alzheimer's disease. Science (2003) 1.52
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler (2013) 1.51
Immunolocalization of Kim-1, RPA-1, and RPA-2 in kidney of gentamicin-, mercury-, or chromium-treated rats: relationship to renal distributions of iNOS and nitrotyrosine. Toxicol Pathol (2008) 1.51
IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease. J Clin Invest (2015) 1.51
Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart (2010) 1.50
Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol (2008) 1.48
Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol (2006) 1.47
Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology (2013) 1.46
Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest (2005) 1.45
Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One (2013) 1.45
Modulation of aquaporin-2/vasopressin2 receptor kidney expression and tubular injury after endotoxin (lipopolysaccharide) challenge. Crit Care Med (2008) 1.44
Metabolic-network-driven analysis of bacterial ecological strategies. Genome Biol (2009) 1.44
Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol (2010) 1.42
Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells. J Immunol (2003) 1.40
Mesenteric lymph nodes are critical for the induction of high-dose oral tolerance in the absence of Peyer's patches. Eur J Immunol (2002) 1.40
Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice. J Immunol (2007) 1.39
Do tubers contain function? Resection of epileptogenic foci in perirolandic cortex in children with tuberous sclerosis complex. Epilepsia (2010) 1.39
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol (2007) 1.36
Induction of kidney injury molecule-1 in homozygous Ren2 rats is attenuated by blockade of the renin-angiotensin system or p38 MAP kinase. Am J Physiol Renal Physiol (2006) 1.36
Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain (2008) 1.34
Gut-tropic T cells that express integrin α4β7 and CCR9 are required for induction of oral immune tolerance in mice. Gastroenterology (2011) 1.34
Systems biology approaches for the study of multiple sclerosis. J Cell Mol Med (2008) 1.33
MicroRNAs are universal regulators of differentiation, activation, and polarization of microglia and macrophages in normal and diseased CNS. Glia (2012) 1.32
Cutting edge: human latency-associated peptide+ T cells: a novel regulatory T cell subset. J Immunol (2010) 1.31
Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2012) 1.31
Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.30
Interplay between effector Th17 and regulatory T cells. J Clin Immunol (2008) 1.29
Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes (2007) 1.29
MyD88-dependent IFN-gamma production by NK cells is key for control of Legionella pneumophila infection. J Immunol (2006) 1.29
MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology (2003) 1.29
An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med (2012) 1.29
Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol (2004) 1.28
Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J Immunol (2008) 1.26
Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation. Proc Natl Acad Sci U S A (2010) 1.26